OBJECTIVE： To systematically review the pregnancy safety of selective 5-serotonin reuptake inhibitor （SSRI） for depression in women underwent in vitro fertilization （IVF） combined with embryo transfer， and to provide evidence-based reference. METHODS： Retrieved from PubMed， EMBase， Cochrane Library， Medline， CBM， CJFD，VIP and Wanfang database， trials about SSRI （trial group） vs. no medicine or placebo alone （control group） for depression in women underwent IVF combined embryo transfer were collected. Meta-analysis was performed by using Rev Man 5.3 statistical software after data extraction and quality evaluation. RESULTS： A total of 4 studies were included， involving 2 122 patients. Results of Meta-analysis showed there was no statistical significance in miscarriage rate [RR＝0.90，95％CI（0.61，1.35），P＝0.62]， pregnancy rate [RR＝1.03， 95％CI（0.73，1.45），P＝0.87] or live birth rate [RR＝1.03，95％CI（0.65，1.63），P＝0.91] between 2 groups. CONCLUSIONS： For depression in women underwent IVF combined with embryo transfer， SSRI do not increase miscarriage rate， decrease pregnancy rate and live birth rate and have no significant effect on the results of IVF combined with embryo transfer.